SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-173750"
 

Search: onr:"swepub:oai:DiVA.org:umu-173750" > Intratumoral retrog...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Intratumoral retrograde microdialysis treatment of high-grade glioma with cisplatin

Tabatabaei, Pedram (author)
Umeå universitet,Neurovetenskaper
Asklund, Thomas (author)
Umeå universitet,Onkologi
Bergström, Per (author)
Umeå universitet,Onkologi
show more...
Björn, Erik (author)
Umeå universitet,Kemiska institutionen,Onkologi
Johansson, Mikael (author)
Umeå universitet,Onkologi
Bergenheim, A. Tommy (author)
Umeå universitet,Neurovetenskaper
show less...
 (creator_code:org_t)
2020-07-14
2020
English.
In: Acta Neurochirurgica. - : Springer. - 0001-6268 .- 0942-0940. ; 162:12, s. 3043-3053
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Purpose: This study evaluates the application of a microdialysis technique for interstitial chemotherapy using cisplatin in high-grade glioma.Method: An in vitro study demonstrated that cisplatin can be administered through retrograde microdialysis and defined the recovery for cisplatin. In a subsequent phase I study, 1–4 microdialysis catheters were implanted in tumor tissue, brain adjacent to tumor (BAT) tissue, and subcutaneous tissue in 10 patients with recurrent high-grade glioma. Cisplatin was administered continuously in daily doses between 0.3 and 3.9 mg for 4 to12 days. Microdialysis samples were continuously collected and analyzed for glucose metabolites, glutamate, glycerol, and cisplatin concentrations. Treatment tolerability was evaluated through clinical monitoring. Quality of life was assessed using the EORTC-QLQ-C30 questionnaire for up to 3 months after treatment.Results: This in vitro study showed that cisplatin could be administrated with a recovery of 41–97%, depending on flowrate, type of catheter, and cisplatin concentration. During the treatment, patients were exposed to a total dose of 1.2–36.8 mg cisplatin. The concentration of cisplatin in BAT, serum, and subcutaneous tissue was close to detection level in all but two patients. A transient neurologic deterioration due to edema was commonly observed, but no systemic side effects were recorded. After onset of treatment, concentrations of glutamate and glycerol were significantly increased in tumor tissue but not in BAT, with a peak after 3 days, and consistent for the rest of the treatment. Five of the patients survived between 153 and 492 days after treatment.Conclusion: This phase I study demonstrates that retrograde microdialysis can be used to administer cisplatin interstitially into high-grade glioma tissue. A high cytotoxicity was detected in tumor tissue, but not in the surrounding brain. Retrograde microdialysis appears to be a clinically useful method for intratumoral drug administration in high-grade glioma.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Keyword

Retrograde microdialysis
Malignant glioma
Cisplatin
Brain microdialysis
Interstitial
Chemotherapy

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view